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low-up. We compared baseline and follow-up WML volume, 
cerebral atrophy and their longitudinal progression exclud-
ing and including the acute ISL, old and de novo stroke le-
sions. A non-parametric test (Wilcoxon’s signed rank test) 
was used to compare the effects.  Results: Among 46 pa-
tients (mean age 72 years), 33 had an ISL visible on MR imag-
ing (median volume 2.05 ml, IQR 0.88–8.88) and 7 of the 33 
had old lacunes at baseline: WML volume was 8.54 ml (IQR 
5.86–15.80) excluding versus 10.98 ml (IQR 6.91–24.86) in-
cluding ISL (p  ! 0.001). At follow-up, median 39 months later 
(IQR 30–45), 3 patients had a de novo stroke lesion; total 
stroke lesion volume had decreased in 11 and increased in 
22 patients: WML volume was 12.17 ml (IQR 8.54–19.86) ex-
cluding versus 14.79 ml (IQR 10.02–38.03) including total 
stroke lesions (p  ! 0.001). Including/excluding lacunes at 
baseline or follow-up also made small differences. Twenty-
two of the 33 patients had tissue loss due to stroke lesions 
between baseline and follow-up, resulting in a net median 
brain tissue volume loss (i.e. atrophy) during follow-up of 
24.49 ml (IQR 12.87–54.01) excluding versus 24.61 ml (IQR 
15.54–54.04) including tissue loss due to stroke lesions (p  ! 
0.001). Including stroke lesions in the WML volume added 
substantial noise, reduced statistical power, and thus in-
creased sample size estimated for a clinical trial.  Conclu-
sions: Failure to exclude even small stroke lesions distorts 
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 Abstract 
 Background: White matter lesions (WML) and brain atrophy 
are important biomarkers in stroke and dementia. Stroke le-
sions, either acute or old, symptomatic or silent, are common 
in older people. Such stroke lesions can have similar signals 
to WML and cerebrospinal fluid (CSF) on magnetic reso-
nance (MR) images, and may be classified accidentally as 
WML or CSF by MR image processing algorithms, distorting 
WML and brain atrophy volume from the true volume. We 
evaluated the effect that acute or old stroke lesions at base-
line, and new stroke lesions occurring during follow-up, 
could have on measurement of WML volume, cerebral atro-
phy and their longitudinal progression.  Methods: We used 
MR imaging data from patients who had originally present-
ed with acute lacunar or minor cortical ischaemic stroke 
symptoms, recruited prospectively, who were scanned at 
baseline and about 3 years later. We measured WML and CSF 
volumes (ml) semi-automatically. We manually outlined the 
acute index stroke lesion (ISL), any old stroke lesions present 
at baseline, and new lesions appearing de novo during fol-
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WML volume, cerebral atrophy and their longitudinal pro-
gression measurements. This has important implications for 
design and sample size calculations for observational stud-
ies and randomised trials using WML volume, WML progres-
sion or brain atrophy as outcome measures. Improved meth-
ods of discriminating between stroke lesions and WML, and 
between tissue loss due to stroke lesions and true brain at-
rophy are required.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 White matter lesions (WML) are common in older 
people and in patients with stroke  [1] and are associated 
with cognitive impairment and dementia, particularly 
in those with WML progression  [2–4] . WML are of in-
creased signal on T 2 -weighted and fluid-attenuated in-
version recovery (FLAIR) magnetic resonance (MR) im-
aging and decreased on T 1 -weighted relative to normal 
white and grey matter. Lacunes, small cavities filled with 
cerebrospinal fluid (CSF) in the basal ganglia, deep 
white matter or brain stem and often asymptomatic, are 
also associated with advancing age, stroke, cognitive de-
cline  [2] and are part of the spectrum of small vessel dis-
ease. Cerebral infarcts, cortical or subcortical, symp-
tomatic or silent  [5] occur in approximately one-third to 
one half of older people on scanning, indicating that si-
lent lesions are more frequent than clinically evident 
stroke  [6] . Stroke lesions may be present at entry to a 
study, either as an acute symptomatic stroke lesion visi-
ble as hyperintense signal on diffusion imaging (index 
stroke lesions; ISL), old lesions including lacunes present 
on the baseline scan, or appear de novo during follow-
up. The resulting brain lesions may have similar signals 
to WML on several MR sequences or result in tissue loss 
and replacement by CSF. WML volume is used increas-
ingly as an outcome measure in clinical trials and obser-
vational studies. The similar signal characteristics of 
WML and stroke lesions mean that the latter may acci-
dentally be included when measuring the burden of 
small vessel disease in the form of WML volume using 
image processing algorithms, resulting in distortion of 
the WML volume.
 Brain atrophy is also common with advancing age and 
associated with cognitive decline and dementia. The 
global cerebral atrophy rate in Alzheimer’s disease (2–3% 
per year) is higher than in healthy controls (0.2–0.5%) 
 [7–9] . Cerebral atrophy rates can be measured as brain 
volume decreases, or CSF increases, using serial regis-
tered MR imaging and could be used as a surrogate mark-
er to predict cognitive decline or monitor disease pro-
gression. However, measurement of brain atrophy rate 
could be distorted by tissue loss caused by focal tissue loss 
following stroke, either cortical or subcortical by forma-
tion of lacunes (subcortical rounded or ovoid cavities be-
tween 3 and 15 mm in diameter with the same intensity 
as CSF on all brain scan sequences  [10] ), where replace-
ment of damaged tissue by CSF, if included in the global 
brain volume measurement, would artificially inflate the 
brain atrophy measurement.
 We evaluated the effect that the ISL, any old lesions at 
baseline and new stroke lesions appearing during follow-
up could have on measurement of WML volume, cerebral 
atrophy and their longitudinal progression.
 Materials and Methods 
 We used imaging data from patients with clinical features of a 
lacunar or mild cortical stroke who were recruited prospectively 
in a study of stroke mechanisms, details published previously  [11] . 
From the 97 patients (51 lacunar stroke and 46 with cortical 
stroke) who were recruited into the original study soon after pre-
senting to hospital with an acute stroke, 46 patients (22 with the 
original diagnosis of lacunar stroke and 24 with the original di-
agnosis of cortical stroke) returned after a median of 39 months 
(IQR 30–45 months) for follow-up scanning. All patients were as-
sessed by a trained stroke physician and underwent diagnostic 
magnetic resonance imaging (MRI) with T 1 -, T 2 * -, T 2 -weighted, 
diffusion-weighted imaging and FLAIR imaging as described 
previously  [11] . About 3 years later, we performed repeat MRI on 
the same 1.5-T MR scanner with identical T 1 sagittal, T 2 , FLAIR 
and gradient recalled echo axial sequences as obtained at baseline. 
The study was approved by the Lothian Research Ethics Commit-
tee and all patients gave written informed consent.
 Image Processing 
 All image processing was performed blind to all clinical and 
other imaging data. Baseline and follow-up images were analyzed 
separately and blind to each other’s results. The intracranial vol-
ume (ICV), ISL, any old infarcts including lacunes at baseline and 
new cortical or subcortical stroke lesions appearing at follow-up 
were manually outlined (masked) on FLAIR, guided by diffusion-
weighted and T 2 -weighted images using a region-growing algo-
rithm in Analyze 9.0 software  [12] . CSF and WML volumes (ml) 
were measured using MCMXXXVI  [12] , a validated image pro-
cessing algorithm for semiautomatic brain tissue segmentation 
(http://sourceforge.net/projects/bric1936/). WML progression is 
the volume difference between follow-up and baseline scans. 
Brain volume was obtained by subtracting CSF from ICV, and 
cerebral atrophy was assessed by brain volume decrease or CSF 
increase between two time points. The tissue loss due to ISL was 
calculated by combining the baseline ISL mask with the follow-up 
CSF mask, the overlapping tissue between those two masks was 
considered as tissue change due to the ISL.
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 Statistical Analysis 
 The distribution of ICV, CSF, WML, stroke lesions and lacu-
nes were not normal (on Kolmogorov-Smirnov tests and inspec-
tion of histograms). We expressed absolute lesion volumes in mil-
lilitres and also adjusted for intersubject differences in head size 
using the ICV. Numeric variables were expressed as median 
(IQR). We compared WML excluding ISL and/or old lesions/la-
cunes with WML including ISL and/or old lesions/lacunes (to test 
if the lacunes, a part of small vessel disease, made a material dif-
ference to the WML volume), and cerebral atrophy excluding ver-
sus including tissue loss due to ISL and/or old lesions/lacunes, 
using non-parametric tests (Wilcoxon’s signed rank test), consid-
ering p  ! 0.05 as statistically significant. Statistical analysis was 
performed with the Statistical Package for the Social Sciences, 
Version 16.0 (SPSS, Chicago, Ill., USA). G * Power 3 was used for 
sample size calculations  [13] .
 Results 
 Among the 46 patients recruited, at baseline the mean 
age was 68 years (SD  8 11), 30 (66%) had hypertension, 4 
(13%) had diabetes, 23 (50%) were lacunar subtype, me-
dian baseline National Institutes of Health Stroke Scale 
(NIHSS) was 2 (IQR 1–3).
 Stroke Lesions 
 At baseline, 33 (72%) had an ISL visible on MRI, me-
dian volume 2.05 ml (IQR 0.88–8.88). The median time 
to follow-up MR was 39 months (IQR 30–45). Three pa-
tients had new stroke lesions on follow-up imaging. The 
stroke lesion volume decreased in 11 and increased in 22 
patients between baseline and follow-up to give a median 
follow-up total stroke lesion volume of 2.43 ml (IQR 0.66–
13.42). However, the volume change ranged from 39.14 ml 
smaller than to 79.97 ml larger than the stroke lesion 
baseline volume ( fig. 1 ; online suppl. table S1, see www.
karger.com/doi/10.1159/000343226 for all online suppl. 
material). Seven of the 33 patients (15% of total patients) 
had an ISL plus one or more lacunes at baseline. The me-
dian baseline lacune volume was 0.30 ml (IQR 0.17–0.47). 
Lacune volume decreased in 2 patients and increased in 
5 patients during follow-up to give a median follow-up 
lacune volume of 0.43 ml (IQR 0.16–0.54). Twenty-two of 
the 33 patients (48% of total patients) had tissue loss due 
to ISL. The median baseline tissue loss due to ISL was 
0.011 ml (IQR 0.00–0.24), and this decreased in 3 patients 
and increased in 19 patients during follow-up to give a 
median follow-up volume of 0.96 ml (IQR 0.07–2.95).
 Effect of Stroke Lesions on WML Volume 
 Among all 46 patients (online suppl. table S2), the me-
dian baseline WML volume was 8.54 ml (IQR 5.86–15.80) 
excluding, and 10.98 ml (IQR 6.91–25.00) including 
stroke lesions (difference Z = –5.012, p  ! 0.001). At follow-
up, the median WML volume was 12.17 ml (IQR 8.54–
19.86) excluding and 14.87 ml (IQR 10.02–38.67) includ-
ing the baseline and any new stroke lesions (difference
Z = –4.937, p  ! 0.001). Including/excluding just lacunes 
alone at baseline or follow-up also made small but sig-
nificant differences (online suppl. table S2).
 Restricting the analysis to just the 33 patients with 
stroke lesions at either time point, or the 26 patients with 
a stroke lesion but no lacunes, or the 7 patients with lacu-
nes (who all also had stroke lesions) gave similar results 
for the proportional difference in WML volume between 
including and excluding ISL, lacunes and new stroke le-
sions as for all 46 patients (online suppl. tables S3, S4, S5). 
However, the absolute true WML volumes were larger in 
patients with a stroke lesion (e.g. baseline WML volume 
10.15 ml, IQR 6.51–18.13) than in those without (e.g. base-
line WML volume 6.63 ml, IQR 4.62–9.47, online suppl. 
table S6). When we adjusted for inter-subject differences 
in intracranial volume, the pattern of results was the 
same.
 Amongst all 46 patients, WML volume increased in 43 
and decreased in 3 patients between baseline and follow-
up (range –1.94 to 33.16 ml) when stroke lesions were
excluded. When stroke lesions were included, 40/46 pa-
tients had an increase and 6 had a decrease in WML vol-
ume, although the median WML volume progression ex-
cluding stroke lesions did not differ significantly from 
that including stroke lesions (difference Z = –1.831, p = 
0.067). However, for each individual patient, the WML 
progression was considerably different including versus 
excluding stroke lesions, with the potential difference in 
WML volume progression being huge, ranging from 
–35.78 to 78.79 ml ( fig.  1 ,  2 ) or between –208.75 and 
163.83% of the baseline WML volume, as shown in the 
increasing length of the IQRs, from WML volume ex-
cluding stroke lesions (e.g. 11.55) to including stroke le-
sions in the WML volume (e.g. 20.21;  table 1 ). Thus in-
cluding the stroke lesions adds substantial noise to the 
measurement of baseline, follow-up and progression of 
WML volume.
 Effect of Stroke Lesions on Atrophy 
 Among all 46 patients, median brain tissue volume ex-
cluding the stroke lesions was 1,155.16 ml (IQR 1,069.97–
1,250.78) at baseline and 1,127.66 ml (IQR 1,054.82–
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Baseline WML
Follow-up WML
Baseline SL
Follow-up SL
Baseline scan Follow-up scan Combined scans
 Fig. 2. Three slices from the same patient 
showing the influence of stroke lesions 
(SL) at baseline and new stroke lesions ap-
pearing during follow-up on WML vol-
ume measurements at baseline, follow-up 
and combined scans. 
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 Fig. 1. Variation in WML volume at base-
line, follow-up and progression due to ex-
cluding/including stroke lesions (SL, acute 
or old) at baseline and new lesions appear-
ing at follow-up. 
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1,204.77) at follow-up; including the stroke lesions it was 
1,154.35 ml (IQR 1,069.97–1,250.63) at baseline and 
1,127.66 ml (IQR 1,052.26–1,204.76) at follow-up. Ex-
pressed in terms of brain atrophy, the median brain atro-
phy volume was 24.49 ml (IQR 12.87–54.01) excluding 
and 24.61 ml (IQR 15.54–54.04) including the stroke le-
sions (Wilcoxon’s signed rank test, Z = –3.915, p  ! 0.001).
 When expressed as a percentage of ICV, the median 
percentage of brain tissue volume in the ICV excluding 
the stroke lesions was 81.04% (IQR 79.16–83.25) at base-
line and 78.45% (IQR 76.04–81.87) at follow-up; includ-
ing the stroke lesions was 81.03% (IQR 79.15–83.25) at 
baseline (Wilcoxon’s signed rank test, Z = –3.724, p  ! 
0.001) and 78.32% (IQR 75.63–81.83) at follow-up (Wil-
coxon’s signed rank test, Z = –4.372, p  ! 0.001).
 For all 46 patients, the median stroke lesions volume 
change between baseline and follow-up was 0.00 ml (IQR 
0.00–0.81). For the 22 patients with tissue loss due to the 
ISL, the median ISL volume change was 0.90 ml (IQR 
0.05–2.89), with volume differences between true brain 
atrophy volume (excluding effect of the ISL) and apparent 
brain atrophy volume (including effect of the ISL) rang-
ing from 0.05 ml less to 21.25 ml more than the true brain 
atrophy volume. This represents up to 1.65% of the base-
line brain tissue volume, or up to 4-fold more than true 
brain atrophy ( fig. 3 ).
 For all 46 patients, the median progression of brain 
atrophy as a percentage of ICV was 1.73% (IQR 0.92–3.55) 
excluding versus 1.77% (IQR 1.03–3.56) including the 
stroke lesions. For the 22 patients with tissue loss due to 
the ISL, the median brain atrophy as a percentage of ICV 
was 2.03% (IQR 1.35–4.50) excluding versus 2.03% (IQR 
1.44–4.94) including the ISL.
 Effect of Stroke Lesions on Sample Size in Studies of 
WML as an Outcome Measure 
 We estimated sample size for a trial of the effect of a 
drug on WML progression, assuming a 20% reduction 
in WML progression with active drug, from 30% in the 
control group to 24% in the treated group. At 80% power 
and alpha of 0.05, the trial would require 1,730 patients 
based on WML volume excluding stroke lesions and 
3,623 patients if the stroke lesions were included in the 
WML volume this difference being largely driven by the 
larger IQR of WML volume when including the stroke 
lesions.
 Discussion 
 WML and brain atrophy are of increasing interest in 
studies of ageing, stroke and dementia. In this fairly typ-
ical cohort of patients who had originally presented with 
an acute lacunar or cortical mild stroke  [11] , we demon-
strated that failure to account for stroke lesions when 
measuring WML volume could increase significantly 
both median baseline and follow-up WML volume by 
about 20% and added substantial noise to the measure-
ment of WML progression. Similarly, for individual pa-
tients, failing to consider the stroke lesions when measur-
ing brain atrophy could increase apparent brain volume 
loss by up to 21.25 ml more than true brain atrophy vol-
ume, representing 1.65% of baseline brain volume, or up 
to 4 times more than true brain atrophy. As WML and 
atrophy are commonly present together in brains of older 
people  [14] as are clinically apparent and silent infarcts 
 [15] , failure to exclude stroke lesions from measures of 
Table 1.  Effect of the stroke lesions (SL) on WML volume IQR at baseline and follow-up and estimates of volume 
change
Group Variable Length of IQR, ml
Patients with WML only (n = 13) WML at baseline 2.88
Patients with stroke lesions (n = 33) WML at baseline 11.55
Patients with stroke lesions (n = 33) WML + SL at baseline 20.21
Patients with WML only (n = 13) WML at follow-up 5.26
Patients with stroke lesions (n = 33) WML at follow-up 13.57
Patients with stroke lesions (n = 33) WML + SL at follow-up 26.08
Patients with WML only (n = 13) difference in WML 4.90
Patients with stroke lesions (n = 33) difference in WML 6.14
Patients with stroke lesions (n = 33) difference in WML + SL 9.83
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both WML and atrophy could confound substantially 
any studies assessing any correlation between risk factors 
for or treatments to prevent stroke, WML and delay atro-
phy. For example, one might think that a drug to prevent 
cardioembolic stroke was reducing WML progression 
when in fact it was preventing recurrent ischaemic stroke 
but not influencing WML progression at all.
 We demonstrate an important consideration for lon-
gitudinal studies of WML, brain atrophy and randomised 
trials of treatments to prevent WML progression or brain 
atrophy, by showing that failure to exclude the stroke le-
sions, even though for example the median ISL volume 
was small (2.05 ml at baseline, 2.43 ml at follow-up), could 
lead to very misleading estimates of WML volumes and 
brain atrophy. Including the stroke lesions in the WML 
volumes adds noise to the WML data at baseline, follow-
up and estimates of progression, resulting in loss of sta-
tistical power. Acute or old stroke lesions may be present 
at entry to a study, may shrink in size or increase and new 
stroke lesions may appear during follow-up. Thus, for the 
individual patient, the effect on WML volume progres-
sion is huge and impossible to predict on an individual 
basis if stroke lesions are included because of the large 
negative or positive effects of the stroke lesions change. 
Reassuringly, the specific effect of lacunes alone on the 
longitudinal WML measurements was small and can 
probably be ignored unless present in large numbers. In-
cluding the stroke lesions in measurement of atrophy also 
adds noise to the brain tissue volume at baseline, follow-
up and estimation of progression.
 This has important implications for design and in par-
ticular for sample size calculations for observational 
studies and randomised trials using WML volume, WML 
volume progression or brain atrophy as an outcome mea-
sure. Statistical power is driven by the IQR, a measure of 
‘noise’ in the system, as well as by the absolute difference 
between groups that one is trying to detect. The added 
noise from stroke lesions and consequent more than dou-
bling of the sample size would substantially increase trial 
duration and costs. Failing to exclude stroke lesions from 
WML volume measurement could obscure the effect of 
treatment on WML progression and mean that poten-
tially effective treatments would be missed in error or 
make ineffective treatments look as if they were benefi-
cial. Visual WML rating scales avoid the problem of in-
farcts contaminating the WML volume. However, they 
are less sensitive to small changes in WML burden than 
are WML volume measures, assuming that the latter are 
accurate. Use of both WML visual scores and volumes in 
a study would help identify discordant volume values that 
might help avoid confounding of WML volume by stroke 
lesions.
 The strengths of this study include the use of a repre-
sentative cohort of patients with a wide range of severities 
of WML. The analyst was blinded to all clinical informa-
tion. We used a carefully tested WML and CSF volume 
measurement method (MCMXXXVI)  [12] that combines 
information from two sequences to reduce errors in 
WML and CSF detection. A neuroradiologist identified 
the infarcts and lacunes and distinguished them from 
WML for image processing.
 The study limitations include that the results may not 
apply to patients with multiple lacunes as only 7 patients 
had a few lacunes. Our population had more stroke le-
sions than in similarly aged subjects without a history of 
stroke, although silent cortical and subcortical stroke le-
sions and lacunes occur in up to 75% of otherwise asymp-
tomatic older volunteers  [6, 16, 17] . It was sometimes dif-
ficult to distinguish the edge of the stroke lesions from 
the WML, but we performed the analysis blind to all
other factors so that any bias is likely to be minimal.
 Further studies are needed to determine the full mag-
nitude of the effect that stroke lesions and lacunes could 
have on WML and cerebral atrophy measurement, and 
find better ways of discriminating between stroke lesions 
and WML and between tissue loss due to stroke lesions 
and true brain atrophy.
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